Keros Therapeutics Inc (KROS)
52.40
-1.59
(-2.94%)
USD |
NASDAQ |
May 20, 16:00
52.40
0.00 (0.00%)
After-Hours: 20:00
Keros Therapeutics Enterprise Value: 1.444B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 1.444B |
| May 16, 2024 | 1.506B |
| May 15, 2024 | 1.521B |
| May 14, 2024 | 1.463B |
| May 13, 2024 | 1.506B |
| May 10, 2024 | 1.516B |
| May 09, 2024 | 1.636B |
| May 08, 2024 | 1.659B |
| May 07, 2024 | 1.675B |
| May 06, 2024 | 1.732B |
| May 03, 2024 | 1.743B |
| May 02, 2024 | 1.618B |
| May 01, 2024 | 1.640B |
| April 30, 2024 | 1.591B |
| April 29, 2024 | 1.672B |
| April 26, 2024 | 1.644B |
| April 25, 2024 | 1.512B |
| April 24, 2024 | 1.586B |
| April 23, 2024 | 1.548B |
| April 22, 2024 | 1.569B |
| April 19, 2024 | 1.660B |
| April 18, 2024 | 1.684B |
| April 17, 2024 | 1.695B |
| April 16, 2024 | 1.649B |
| April 15, 2024 | 1.638B |
| Date | Value |
|---|---|
| April 12, 2024 | 1.671B |
| April 11, 2024 | 1.790B |
| April 10, 2024 | 1.752B |
| April 09, 2024 | 1.859B |
| April 08, 2024 | 1.837B |
| April 05, 2024 | 1.818B |
| April 04, 2024 | 1.783B |
| April 03, 2024 | 1.865B |
| April 02, 2024 | 1.867B |
| April 01, 2024 | 1.970B |
| March 31, 2024 | 1.945B |
| March 28, 2024 | 2.051B |
| March 27, 2024 | 1.995B |
| March 26, 2024 | 2.048B |
| March 25, 2024 | 2.053B |
| March 22, 2024 | 2.039B |
| March 21, 2024 | 2.152B |
| March 20, 2024 | 2.075B |
| March 19, 2024 | 1.979B |
| March 18, 2024 | 1.967B |
| March 15, 2024 | 2.092B |
| March 14, 2024 | 2.002B |
| March 13, 2024 | 2.103B |
| March 12, 2024 | 2.099B |
| March 11, 2024 | 2.055B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
397.04M
Minimum
Jun 28 2022
2.205B
Maximum
Mar 08 2024
967.90M
Average
923.74M
Median
Jul 17 2023
Enterprise Value Benchmarks
| Morphic Holding Inc | 805.47M |
| NovaBay Pharmaceuticals Inc | 5.156M |
| Palatin Technologies Inc | 22.26M |
| iBio Inc | 25.46M |
| Theriva Biologics Inc | -8.901M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.11M |
| Revenue (Quarterly) | 0.083M |
| Total Expenses (Quarterly) | 48.57M |
| EPS Diluted (Quarterly) | -1.21 |
| Profit Margin (Quarterly) | -51.94K% |
| Earnings Yield | -9.83% |
| Normalized Earnings Yield | -10.14 |